SPRY — ARS Pharmaceuticals, Inc
NASDAQ · Healthcare · Biotechnology
$5.91
+$0.14 (+2.43%)
ARS Pharmaceuticals, Inc (SPRY) is a biotechnology company listed on NASDAQ. It is led by Richard E. Lowenthal M.B.A., M.S., MSMSEL, based in 11682 El Camino Real, San Diego, CA, United States, 92130, with about 154 employees. ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
Latest reported SPRY revenue for 2025-09-30 was $32.5M. Net income was -$51.2M. Revenue was up 106.8% from 2025-06-30 to 2025-09-30. SPRY currently screens at market cap $983.1M.
Use this SPRY page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the SPRY quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the SPRY SEC filings page. Lician reads the product cache first so this HTML stays unique to ARS Pharmaceuticals, Inc even when a live quote feed is slow.
About ARS Pharmaceuticals, Inc
ARS Pharmaceuticals, Inc., a biopharmaceutical company, develops and commercializes treatments for severe allergic reactions in the United States and internationally. The company is involved in the development of neffy, a needle-free intranasal delivery of epinephrine for emergency treatment of Type I allergic reactions, including anaphylaxis. ARS Pharmaceuticals, Inc. was founded in 2015 and is headquartered in San Diego, California.
SPRY Key Statistics
Market Cap
$983.10M
Volume
1.16M
Previous Close
$5.72
Day Range
$5.67 – $6.09
P/B Ratio
16.04
EPS
$0.08
Revenue
$89.15M
Net Income
$8.00M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+297063.3%
Profit Margin
9.0%
Employees
154
SPRY Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|
| Revenue | $89.15M | $30.00K | $1.32M | $5.51M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | $8.00M | -$54.37M | -$34.68M | -$20.24M |
| EPS (Diluted) | $0.08 | -$0.57 | -$0.87 | -$0.70 |
Total Assets
$351.15M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$50.82M
Operating Cash Flow
$13.55M
Free Cash Flow
$0.00
ARS Pharmaceuticals, Inc Company Information
- Co-Founder, CEO & Director
- Richard E. Lowenthal M.B.A., M.S., MSMSEL
- Headquarters
- 11682 El Camino Real, San Diego, CA, United States, 92130
- Website
- ars-pharma.com
- Phone
- 858 771 9307
- IPO / Founded
- 2020-12-04
- Sector
- Healthcare
- Industry
- Biotechnology